Zobrazeno 1 - 10
of 21
pro vyhledávání: '"K Y, Look"'
Autor:
Scott McKane, Patricia LoRusso, Michael S. Gordon, K Y Look, Robert Ilaria, Dinesh P. de Alwis, David S. Mendelson, Margaret M. Wagner
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:21-27
To determine the recommended/maximum tolerated dose (MTD), pharmacokinetics (PK), and safety profile of tasisulam sodium (hereafter tasisulam), a novel anticancer agent.In this phase I study, tasisulam was administered as a 24-h continuous intravenou
Publikováno v:
International Journal of Gynecologic Cancer. 14:104-109
A functional and widely accepted definition of microinvasive cervical adenocarcinoma remains elusive. The purpose of this study was to determine at which depth of invasion the likelihood of lymph node metastasis or disease recurrence was so small tha
Publikováno v:
Obstetrics & Gynecology. 89:848-850
Keratoacanthomas are neoplastic proliferations of keratinocytes thought to originate from follicular epithelium. There is only one previously reported case in which keratoacanthoma involved the vulva.A 54-year-old woman presented with a nonulcerated
Autor:
K Y, Look
Publikováno v:
European journal of gynaecological oncology. 25(5)
To review the role of lymphadenectomy (LND) for patients with endometrial adenocarcinoma.A review was undertaken of the English Language literature dealing with the role of LND for patients with endometrial adenocarcinoma (EC).The prognostic value of
Publikováno v:
Anticancer research. 21(1A)
Thymidine kinase 1 (TK 1 EC. 2.7.1.21) the most specific and cell-cycle regulated salvage enzyme for pyrimidine nucleoside supply of DNA synthesis is a promising target to rationally designed chemo- and other therapies. The present study was undertak
Autor:
K Y, Look
Publikováno v:
European journal of gynaecological oncology. 21(5)
Publikováno v:
Gynecologic oncology. 79(3)
The aim of this study was to develop an outcomes measure, which incorporates patient reported information, for The Society of Gynecologic Oncologists (SGO) to establish benchmarks in the treatment of endometrial cancer and demonstrate quality to thir
Publikováno v:
European journal of gynaecological oncology. 21(3)
The purpose was to identify novel targets for the chemotherapy of ovarian carcinoma.Assays were worked out to measure the activities of P1 kinase, PIP kinase and PLC in ovarian carcinoma samples and in OVCAR-5 cells and to compare the activities to t
Publikováno v:
Cancer. 85(8)
Transforming growth factor-beta (TGF-beta) is known to inhibit primary epithelial ovarian carcinoma cells. The mechanism by which this inhibitory response is achieved is poorly understood. Furthermore, whether this response is consistent in cells fro
Publikováno v:
Cancer biochemistry biophysics. 16(1-2)
The activity of uridine kinase (ATP: uridine 5'-phosphotransferase; EC 2.7.1.48), the rate-limiting enzyme of the UMP salvage pathway, was measured in human ovaries and ovarian carcinomas, in a spectrum of six rat hepatomas of different growth rates